In a recent study published in The Lancet Regional Health Western Pacific, researchers compare the immunogenicity, reactogenicity, and safety of a half-dose Pfizer-BioNTech BNT162b2 coronavirus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback